CRXT logo

CRXT Stock

Profile

Full Name:

Clarus Therapeutics Holdings, Inc.

Sector:

Healthcare

Industry:

Drug Manufacturers - General

Country:

United States

IPO:

07 September 2021

Indexes:

Not included

Website:

http://clarustherapeutics.com

Description:

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$13.96 M(+119.14% YoY)

Annual EPS

-$5.72(-77.62% YoY)

PE Ratio

-

Annual ROE

255.15%

Annual Debt To Equity

-2.66

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 18, 2022

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

23 Aug '22 Needham
Hold
22 Aug '22 Maxim Group
Hold
17 May '22 Truist Securities
Buy
17 May '22 Needham
Buy
31 Mar '22 Needham
Buy
13 Oct '21 Truist Securities
Buy
06 Oct '21 Needham
Buy
29 Sept '21 Maxim Group
Buy
20 Sept '21 Oppenheimer
Outperform
20 Sept '21 Cantor Fitzgerald
Overweight

Screeners with CRXT included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$10.45
CRXT price is currently at an all-time high

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

+119.14%
CRXT annual revenue is up +119.14% over the past 3 years

Annual Revenue Estimate

$18.94 M
CRXT annual revenue is currently -26.31% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

-1034.8%
CRXT annual net profit is down -1034.8% over the past 3 years

Annual EPS 3-Year Change

-77.62%
CRXT annual earnings per share is down -77.62% over the past 3 years

Annual EPS Estimate

-$1.00
CRXT annual earnings per share is currently +472.00% higher than the consensus analysts' forecast

Annual Gross Profit

$11.24 M
CRXT annual gross profit is $11.24 million

Annual Operating Profit

-$39.73 M
CRXT annual operaing income is -$39.73 million

Annual Operating Profit 3-Year Change

+15.78%
CRXT annual operaing income is up +15.78% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

255.15%
CRXT annual return on equity is 255.15%

Annual ROA

-114.24%
CRXT annual return on assets is -114.24%

Annual EBIT

-$24.72 M
CRXT annual earnings before interest & taxes is -$24.72 million

Annual EBITDA

-$24.70 M
CRXT annual earnings before interest, taxes, depreciation & amortization is -$24.70 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

0.57
CRXT annual quick ratio is 0.57

Annual Current Ratio

0.78
CRXT annual current ratio is 0.78

Annual Total Assets

$51.71 M
CRXT annual total assets is $51.71 million

Annual Current Assets

$51.64 M
CRXT annual total current assets is $51.64 million

Annual Total Liabilities

$67.63 M
CRXT annual total liabilities is $67.63 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-5.31%
CRXT annual cash flow from operations is down -5.31% over the past 3 years

Annual CFI 3-Year Change

+60.32%
CRXT annual cash flow from investing activities is up +60.32% over the past 3 years

Annual CFF 3-Year Change

+33.4%
CRXT annual cash flow from financing activities is up +33.4% over the past 3 years

Annual CAPEX

$25.00 K
CRXT annual capital expenditures is $25.00 thousand

Annual CAPEX 3-Year Change

-60.32%
CRXT annual capital expenditures is down -60.32% over the past 3 years

Annual FCF

-$43.81 M
CRXT annual free cash flow is -$43.81 million

Annual FCF 3-Year Change

-5.21%
CRXT annual free cash flow is down -5.21% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Clarus Therapeutics Holdings?
  • What is the ticker symbol for Clarus Therapeutics Holdings?
  • Does Clarus Therapeutics Holdings pay dividends?
  • What sector is Clarus Therapeutics Holdings in?
  • What industry is Clarus Therapeutics Holdings in?
  • What country is Clarus Therapeutics Holdings based in?
  • When did Clarus Therapeutics Holdings go public?
  • Is Clarus Therapeutics Holdings in the S&P 500?
  • Is Clarus Therapeutics Holdings in the NASDAQ 100?
  • Is Clarus Therapeutics Holdings in the Dow Jones?
  • When was Clarus Therapeutics Holdings's last earnings report?
  • When does Clarus Therapeutics Holdings report earnings?

What is the primary business of Clarus Therapeutics Holdings?

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

What is the ticker symbol for Clarus Therapeutics Holdings?

The ticker symbol for Clarus Therapeutics Holdings is NASDAQ:CRXT

Does Clarus Therapeutics Holdings pay dividends?

No, Clarus Therapeutics Holdings does not pay dividends

What sector is Clarus Therapeutics Holdings in?

Clarus Therapeutics Holdings is in the Healthcare sector

What industry is Clarus Therapeutics Holdings in?

Clarus Therapeutics Holdings is in the Drug Manufacturers - General industry

What country is Clarus Therapeutics Holdings based in?

Clarus Therapeutics Holdings is headquartered in United States

When did Clarus Therapeutics Holdings go public?

Clarus Therapeutics Holdings's initial public offering (IPO) was on 07 September 2021

Is Clarus Therapeutics Holdings in the S&P 500?

No, Clarus Therapeutics Holdings is not included in the S&P 500 index

Is Clarus Therapeutics Holdings in the NASDAQ 100?

No, Clarus Therapeutics Holdings is not included in the NASDAQ 100 index

Is Clarus Therapeutics Holdings in the Dow Jones?

No, Clarus Therapeutics Holdings is not included in the Dow Jones index

When was Clarus Therapeutics Holdings's last earnings report?

Clarus Therapeutics Holdings's most recent earnings report was on 18 November 2022

When does Clarus Therapeutics Holdings report earnings?

The date for Clarus Therapeutics Holdings's next earnings report has not been announced yet